Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319411 | 0.84 | AR (0.44) | ARF2CFDMAOAMAOB | |
| SCHEMBL27248704 | 0.83 | AR (0.45) | ARNOS1NOS2F2CFD | |
| SCHEMBL29919980 | 0.83 | AR (0.41) | ARNOS1NOS2F2CFD | |
| SCHEMBL3985564 | 0.83 | AR (0.41) | ARNOS1NOS2F2CFD | |
| SCHEMBL27248587 | 0.80 | ELANE (0.42) | ARNOS1NOS2F2CFD | |
| SCHEMBL4492747 | 0.80 | NOS1 (0.44) | ARNOS1NOS2F2CFD | |
| SCHEMBL27248989 | 0.79 | MAOA (0.38) | ARNOS1NOS2F2CFD | |
| SCHEMBL27248655 | 0.79 | MAOA (0.38) | ARNOS1NOS2MAOAMAOB | |
| SCHEMBL4491356 | 0.77 | NOS1 (0.42) | ARNOS1NOS2F2CFD | |
| SCHEMBL4502778 | 0.77 | NOS1 (0.42) | ARNOS1NOS2F2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340556-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7109338-B2 | For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1380575-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6541470-B1 | Have a potent antiviral activity against picornaviruses and rotaviruses. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | AR 308/4885NOS1 2705/4885NOS2 2674/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | AR 1857/4885NOS1 2144/4885NOS2 2452/4885 |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, PEPD, ABCB11 | AR 4211/4885NOS1 2786/4885NOS2 2703/4885 |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MAVS, IRF3, EIF2AK2 | AR 4416/4885NOS1 1267/4885NOS2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.